To determine whether the hypoprothrombinemia associated with antibiotics containing a 1-methyl-5-thiotetrazole (MUT) group is a result of the presence of the MUT group, rats were maintained on a vitamin K-deficient diet for 10 days and then received either intravenous moxalactam or cefotaxime or oral MUT for two additional days. MUT and moxalactam, which contains the MUT group, prolonged prothrombin time. Cefotaxime, which lacks the MUT group, had no effect.
with the development of hypoprothrombinemia in humans. These antibiotics include cefamandole (5) , cefoperazone (9) , and moxalactam (8) . The mechanism for the hypoprothrombinemia is in dispute. One hypothesis is that these antibiotics, which are secreted in the bile, destroy intestinal bacteria which produce vitamin K, a necessary cofactor in the synthesis offour of the clotting factors (4) . Another theory is that the MTT which is released from the intact antibiotic is able to inhibit gamma carboxylation of glutamic acid (7, 11) , the vitamin K-dependent step in the synthesis of the clotting factors. This hypothesis is supported by the observation that MUT inhibits the gamma carboxylation of glutamic acid in an in vitro rat liver microsomal system (6) . To test the in vivo relevance of this finding, we examined the effects of moxalactam, cefotaxime, and MTT in rats maintained on a vitamin K-free diet. Moxalactam contains the MTT group; cefotaxime does not (Fig. 1) . Both moxalactam and MTT produced hypoprothrombinemia in rats maintained on vitamin K-deficient diets for 10
days. There was a three-to fourfold prolongation of prothrombin time within 48 h of the first dose of these drugs (Table 1 ).
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The ability of cefotaxime, a drug which does not contain the MTT group, to produce hypoprothrombinemia was examined and compared with that of moxalactam. Cefotaxime was not able to produce a prolongation of the prothrombin time, but under the same conditions, moxalactam again increased the prothrombin time over fivefold ( thrombin time (1) . These human studies and the studies in rats on normal diets may be analogous in that normal levels of vitamin K were present in both cases. The large antibiotic dose used in our studies, 3 glkg, was chosen because it is simnilar to the upper limit of the doses used to test these drugs in normal animals. Future studies will determine the minimum doses of both moxalactam and MTT necessary to produce hypoprothrombirnemia.
MTT was administered orally because the gastrointestinal tract may be where MTT is liberated from the parent antibiotic. Evidence for the release of MTT from the parent antibiotic in humans is the finding of free MTT in the plasma of subjects who have received moxalactam (2) . MTT has also been detected in the urine of subjects who have received cefmetazole, an antibiotic with an MTT side group (10) . It has been hypothesized that the intact MTT-containing antibiotic is secreted into the bile and is then degraded in the intestine to release the MTT group. MTT is located in betalactani antibiotics in a "leaving group" position secondary to the lactam bonid cleavage (3). This cleavage may be due to nucleoihilic attack by bacterial enzymes or the chemical environment. After its release from the parent antibiotic, MTT could then be absorbed with sUibsequent inhibition of the carboxylase system in the liver. Since only a fraction of the parent antibiotic is secreted in the bile, atnd since MTT is only about one-fifth of the molecular weight of the intact antibiotic, the oral dose of MTT needed to produce hypoprothrombinemia may be less than that used in our studies. 
